| Budget Amount *help |
¥17,030,000 (Direct Cost: ¥13,100,000、Indirect Cost: ¥3,930,000)
Fiscal Year 2014: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2013: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2012: ¥7,800,000 (Direct Cost: ¥6,000,000、Indirect Cost: ¥1,800,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we aim to elucidate potential resistance mechanisms in urological cancer in vivo model by exome sequencing. We have generated several cohort of patient-derived primary xenograft model, and some of which develop complete resistance to temsirolimus or sunitinib with continuous drug exposure. We performed whole exome sequencing. Comparison of resistant and control data identified common Non-synonymous single nucleotide variants (SNVs) among resistant tumor that were absent in control tumor. Further studies to explore whether these variants arise in urological cancer are expected to reveal the clinical relevance of genetic alterations identified in these model system.
|
